Lakewood-Amedex Biotherapeutics Inc(LABT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -10.34 | Insider Own | 33.38% | Shs Outstand | 2.2M | Perf Week | -33.56% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.6M | Perf Month | -43.14% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -1.33 | Inst Own | 6.49% | Short Float | 9.68% | Perf Quarter | -84.18% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 67.96% | Short Ratio | 0.01 | Perf Half Y | -98.17% |
| Sales | 0.00B | P/B | 0.18 | EPS next 5Y | - | ROA | -225.45% | Short Interest | 0.15M | Perf YTD | -99.55% |
| Book/sh | 2 | P/C | 0.19 | EPS past 3/5Y | 17.02% - | ROE | -402.84% | 52W High | -99.63% ($98.20) | Perf Year | - |
| Cash/sh | 1.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -169.64% | 52W Low | 112.92% ($0.17) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -140.44% | Gross Margin | - | Volatility(W/M) | 25.09% 25.47% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.7 | EPS Q/Q | -769.45% | Profit Margin | - | RSI (14) | 37.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.7 | Sales Q/Q | - | SMA20 | -2.71% ($0.37) | Beta | - | Target Price | $7.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/09/02 | SMA50 | -64.96% ($1.03) | Rel Volume | 0.08 | Prev Close | $0.4 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -94.71% ($6.81) | Avg Volume(3M) | 14.84M | Price | $0.36 |
| IPO | 2026/4/23 | Option/Short | No/Yes | Trades | 1722 | Volume | 1,159,903 | Change | -9.06% |
An early clinical-stage biotech company developing topical antibacterial drugs to treat antibiotic-resistant infections. Founded in 2015 and headquartered in Manatee County, Florida, the company began trading on the Nasdaq Capital Market in April 2026.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 8% of its average volume.
LABT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.5%.
Tap to view numbers
It ranks #592 of 597 in the industry
Based on market cap of $1M.
GOVX#589 Geovax Labs Inc $1M PER - 
MTNB#590 Matinas Biopharma Holdings Inc $1M PER - 
VRAX#591 Virax Biolabs Group Ltd $1M PER - LABT#592 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
SPRC#593 SciSparc Ltd $1M PER - 
FAQ
What kind of company is LABT?
LABT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LABT?
The market cap of LABT is approximately $1M, ranking 5,862 within its sector.
What is the 52-week high and low for LABT?
LABT has recorded a 52-week high of $98.20 and a low of $0.17.
